VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 20, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce that it is has engaged GrowthPoint Group to assist in strategic management. GrowthPoint's Neil Belenkie and Nigel Terrett, both having significant corporate and life sciences backgrounds, will lead the project.
"GrowthPoint Group has a hands-on, results-driven approach that has helped many companies improve performance and build a sustainable business," said Dr. Howard Verrico, President & CEO of Sirona Biochem. "Sirona Biochem is at a pivotal stage of development with programs maturing to a partnering stage and it's key to execute our plans effectively. With GrowthPoint, we expect to develop a targeted plan that will bring the best possible value for the company," added Dr. Verrico.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
About GrowthPoint Group
The GrowthPoint Group is a team of senior business leaders who specialize in business analysis and planning, revenue generation and strategic growth. With proven track records from a broad spectrum of industries, GrowthPoint provides hands-on execution to ensure companies are given sustainable business solutions. For more information, please visit www.growthpointgroup.com.
About Neil Belenkie
Neil Belenkie, a winner of Business in Vancouver Magazine's Top 40 Under 40, brings his significant health care experience to Sirona Biochem. His award-winning career in life sciences includes leadership in sales, market research, marketing, and medical education. At The GrowthPoint Group, Neil leads a team of seasoned individuals including corporate leaders from health care and life science companies.
About Nigel Terrett
Nigel Terrett brings his vast life sciences experience to Sirona Biochem. Nigel's previous roles include Chief Strategic Officer for LifeLabs Inc., Canada's largest private medical diagnostics company, Senior VP and GM of LifeLabs BC, Chief Information Officer for MDS Inc and Vice-President, IT at MDS Diagnostics. Nigel was also instrumental in launching Excelleris Technologies where he served as Chairman of the Board. More recently, Nigel has used his valuable experience to provide advisory services to the Biotech industry.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.